Three-Drug attack on breast cancer before surgery
NCT ID NCT03573648
Summary
This study is testing a new combination of three drugs given before surgery for early-stage, hormone-sensitive breast cancer. The goal is to see if adding an immunotherapy drug (avelumab) to standard hormone-blocking treatments helps shrink tumors more effectively. Researchers will monitor how well patients respond and track side effects to see if this approach is safe and beneficial.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Allegheny Health Network
Pittsburgh, Pennsylvania, 15224, United States
-
Sibley Memorial Hospital
Washington D.C., District of Columbia, 20016, United States
-
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, 21287, United States
-
University of Alabama at Birmingham
Birmingham, Alabama, 35233, United States
Conditions
Explore the condition pages connected to this study.